Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has been assigned an average recommendation of “Buy” from the eight research firms that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $29.00.
A number of brokerages have weighed in on SPPI. BidaskClub downgraded shares of Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 3rd. HC Wainwright raised their target price on shares of Spectrum Pharmaceuticals to $33.00 and gave the company a “buy” rating in a research note on Monday, February 5th. B. Riley began coverage on shares of Spectrum Pharmaceuticals in a research note on Monday, December 18th. They set a “buy” rating and a $26.00 target price for the company. Zacks Investment Research raised shares of Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 12th. Finally, Jefferies Group raised their target price on shares of Spectrum Pharmaceuticals to $25.00 and gave the company a “buy” rating in a research note on Friday, October 20th.
Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) traded up $0.92 during midday trading on Friday, hitting $21.28. 975,100 shares of the company’s stock were exchanged, compared to its average volume of 977,129. Spectrum Pharmaceuticals has a fifty-two week low of $5.47 and a fifty-two week high of $23.50. The company has a market capitalization of $2,049.48, a P/E ratio of -21.49 and a beta of 1.64. The company has a quick ratio of 4.89, a current ratio of 5.04 and a debt-to-equity ratio of 0.33.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.